NEXUS Biosystems has announced that it has renewed its worldwide marketing agreement with Bruker AXS to continue to globally market, sell and support the NEXUS Crystal Farm line of products. The range of products is an expanding line of automated instrumentation focused on protein crystallography research.
NEXUS Biosystems has announced that it has renewed its worldwide marketing agreement with Bruker AXS to continue to globally market, sell and support the NEXUS Crystal Farm line of products. The range of products is an expanding line of automated instrumentation focused on protein crystallography research.
At the centre of the Crystal Farm range is a high-resolution imaging system that has the ability to create image hanging, sitting or micro-batch drops in virtually all plate types. The Crystal Navigator is a scalable web-based software that can be used to directly or remotely access the system control and image analysis. This line of automated instrumentation products is available in three different models, the CF-150, CF-400 and the CF-5000, which each address different research needs.
For more information visit the companies' websites at www.nexusbio.com and www.bruker-axs.com
Waters has been awarded with its fifth consecutive Omega Northface Scoreboard SM award for exceeding customer expectations in service and satisfaction during 2005. The award is administered by the Omega Management Group that implements customer satisfaction and retention programmes.
The award was formally presented at the SCORE Conference 2006 in Boston, Massachusetts, USA. Omega measures customer satisfaction via customer input and had surveyed 3100 customers in 20 countries. According to the results Waters received a score of 4 or higher out of a possible 5 in technical support, field service, sales process, customer service and product quality.
For more information visit the company's website at www.waters.com
An industry-transforming transaction has been announced by Thermo Electron and Fisher Scientific International. The boards of directors from both companies have unanimously approved a definitive agreement to combine the two companies in a tax-free, stock-for-stock exchange.
This merger is expected to produce 2007 revenues of $9 billion and the newly formed company will be called Thermo Fisher Scientific. Under the terms of the agreement, Fisher will receive 2.00 shares of Thermo common stock for each share of Fisher stock it owns. Upon completion of the transaction approximately 39% of the combined company will be owned by Thermo's shareholders and 61% by Fisher's. The transaction will be treated as a reverse merger with Thermo as the acquirer.
Although approval by both companies' shareholders and customary closing conditions and regulatory approvals are still required, the transaction is expected to close in the fourth quarter of this year.
The companies hosted a webcast and conference call on the release of this information, of which the webcast and accompanying slides as well as an audio archive of the call are available on both companies' websites.
For more information visit the websites at www.thermo.com and www.fisherscientific.com
The second highest Austrian research prize has been awarded to the Christian Doppler Laboratory for mycotoxin research. The laboratory is based at the Department for Agrobiotechnology Tulln (IFA-Tulln) of the University of Natural Resources and Applied Life Sciences, Vienna.
The Dr Wolfgang Houska Award was open to all scientific and engineering research groups in Austria but the €50000 prize was given to Professor Rudi Krska and his team for their development of a fast and reliable method of mycotoxin detection.
The winning research group used a 4000 Q TRAP LC–MS–MS system from Applied Biosystems/MDS Sciex to simultaneously measure 10 different mycotoxins in less than 7 minutes. However, after receiving the award the group has achieved measurement of 40 mycotoxins in 40 minutes.
For more information visit Applied Biosystems' website at http://europe.appliedbiosystems.com
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
2024 EAS Awardees Showcase Innovative Research in Analytical Science
November 20th 2024Scientists from the Massachusetts Institute of Technology, the University of Washington, and other leading institutions took the stage at the Eastern Analytical Symposium to accept awards and share insights into their research.